ARTICLE | Company News
Kode Biotech, Agalimmune deal
July 13, 2015 7:00 AM UTC
Kode granted Agalimmune exclusive rights to use Function-Spacer-Lipid (FSL) cell surface membrane technology in the field of intratumoral injection to treat cancer. Kode is eligible to receive up to $...